Antisense Therapeutics to commence muscular dystrophy trials | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Antisense Therapeutics to commence muscular dystrophy trials


Antisense Therapeutics is planning to undertake a clinical trial of its immunomodulatory therapy ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).

The trial is designed to assess the drug’s effects on the inflammation associated with this rare and incurable muscle wasting disease in children.

DMD is caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.

https://www.duchennexchange.org/wp-content/uploads/2017/07/antisense-therapeutics.jpg